For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Semax: origin, structure and research history

Research Library › Neuropeptides

Semax is a synthetic seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4–10) fragment of adrenocorticotropic hormone, with a Pro-Gly-Pro tail added for stability. It was designed in the 1980s by Igor Ashmarin of Moscow State University and chemists led by Nikolay Myasoedov at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is registered as a prescription medicine in Russia but is not FDA-approved; an FDA advisory committee voted 8–5 in July 2026 to recommend allowing pharmacy compounding, with no final FDA decision as of 22 Oct 2026.

Key facts

TypeSynthetic seven-amino-acid peptide (heptapeptide)
SequenceMet-Glu-His-Phe-Pro-Gly-Pro
Derived fromACTH(4–10), a fragment of adrenocorticotropic hormone (melanocortin family)
First describedDesign work began in the early 1980s; first Russian registration in 1994
Developed byIgor Ashmarin (Moscow State University) and Nikolay Myasoedov's group (Institute of Molecular Genetics, Russian Academy of Sciences)
Designed targetACTH-derived melanocortin peptide; mechanism described by FDA as poorly understood
Regulatory status (Oct 2026)Not FDA-approved; prescription medicine in Russia; PCAC voted 8–5 in favor of compounding eligibility in July 2026, no final FDA decision

Who developed it

Semax came out of a collaboration between two Moscow institutions. Academician Igor Ashmarin, a physiologist at Moscow State University, defined the research goal, and a team of peptide chemists led by Nikolay Myasoedov at the Institute of Molecular Genetics of the Russian Academy of Sciences carried out the synthesis [1][2]. The developers later summarized roughly 15 years of design and study work in a 1997 review [3].

What it was designed to target

The starting point was adrenocorticotropic hormone (ACTH), the pituitary hormone that signals the adrenal glands to release cortisol. ACTH belongs to the melanocortin family of peptides. Researchers had long studied a short internal piece of it, ACTH(4–10), which is cleared from the body within minutes.

Semax keeps the first four residues of that fragment (Met-Glu-His-Phe) and replaces the final three with the tripeptide Pro-Gly-Pro. According to its developers and the FDA’s 2026 review, the substitution was intended to make the molecule far more resistant to breakdown while removing the hormonal, adrenal-stimulating activity of the parent ACTH [2][4].

In preclinical work, a 2006 rat study examined Semax in relation to expression of BDNF (brain-derived neurotrophic factor) and its receptor trkB in the hippocampus [5]. This remains a proposed mechanism. The FDA briefing document describes Semax as acting through poorly understood mechanisms [2].

Why it was created

Ashmarin’s original brief, as recounted by colleagues, called for a fundamentally new kind of memory-related compound [1]. Early research focused on cognitive performance under stressful conditions. The program later shifted toward neurology, and Semax was registered in Russia for indications related to stroke and other neurological conditions [4][6].

Research timeline

  • Early 1980s: Design work on a stabilized ACTH(4–10) analog begins in Moscow [3].
  • 1994: First Russian registration of a 0.1% Semax solution [7].
  • 1997: Developers publish a review of 15 years of design and study [3].
  • 2006: Rat study links Semax to hippocampal BDNF and trkB expression [5].
  • 2011: Current Russian registration certificate issued to Peptogen [6].
  • July 2026: FDA Pharmacy Compounding Advisory Committee votes 8–5 on Semax [8][9].

Regulatory status as of October 2026

As of 22 Oct 2026, Semax is a prescription medicine in Russia and is not FDA-approved in the United States [6].

At its 23–24 July 2026 meeting, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) evaluated Semax-related bulk drug substances for the 503A bulks list. Both parties that had nominated Semax withdrew their nominations, but the FDA reviewed it anyway. FDA staff recommended against inclusion; the committee voted 8–5 in favor [8][10][11]. The vote is advisory, and no final FDA decision had been published as of 22 Oct 2026 [11].

On 14 Oct 2026 the FDA sent an interim access policy for compounding with certain peptides to the White House for review. Its text and peptide list were not public and it was not final as of 22 Oct 2026 [12].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who invented Semax?

Semax was developed in Moscow by Academician Igor Ashmarin of Moscow State University together with peptide chemists led by Nikolay Myasoedov at the Institute of Molecular Genetics, Russian Academy of Sciences.

What is Semax derived from?

It is derived from ACTH(4–10), a fragment of adrenocorticotropic hormone. Four residues of that fragment are kept and the last three are replaced with Pro-Gly-Pro for stability.

Is Semax FDA approved?

No. As of 22 Oct 2026 Semax is not FDA-approved. An FDA advisory committee voted 8–5 in July 2026 to recommend allowing pharmacy compounding, but the FDA had not issued a final decision.

When was Semax first registered?

Semax was first registered in Russia in 1994, and its current Russian certificate dates from 2011.

Is Semax related to Selank?

Yes. Both were developed at the same Moscow institute and both carry the same Pro-Gly-Pro stabilizing tail, but Semax derives from ACTH while Selank derives from the immune peptide tuftsin.

Sources

  1. Kamensky AA, Dubynin VA. Igor Petrovich Ashmarin and the Department of Human and Animal Physiology, MSU. Neirokhimiya. 2022;39(4):333–339. doi:10.31857/S1027813322040112 Link
  2. U.S. FDA, CDER. Briefing document: evaluation of semax-related bulk drug substances for the 503A bulks list. Pharmacy Compounding Advisory Committee, 23–24 Jul 2026. Link
  3. Ashmarin IP et al. A nootropic adrenocorticotropin analog 4-10, Semax (15 years' experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420–430. PMID 9173745. Link
  4. Zhuikova SE. Physiological and clinical effects of Semax, a synthetic ACTH4–10 analogue: mechanisms of action. Integrative Physiology. 2022;3(2):204–220. Link
  5. Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. PMID 16996037. Link
  6. RLS Encyclopedia (Russia). Semax: product monograph and current registration P N000812/01 (29 Dec 2011, Peptogen). Link
  7. RLS Encyclopedia (Russia). Registration record, Semax 0.1% solution, no. 94/294/10, 20 Dec 1994. Link
  8. Eglovitch JS. FDA advisory committee backs two more peptides, rejects one for compounding list. Regulatory Focus (RAPS), 24 Jul 2026. Link
  9. Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
  10. U.S. FDA, CDER. Briefing document overview (nominators, withdrawals, FDA proposals), PCAC 23–24 Jul 2026. Link
  11. Binzak Blumenfeld BA et al. (Buchanan Ingersoll & Rooney). FDA advisory committee voted yes on six peptides. Now what? 18 Aug 2026. Link
  12. Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top